Hemispherx shares boost on FDA Ampligen study hope
This article was originally published in Scrip
Executive Summary
Shares in the US biotech company Hemispherx BioPharma jumped by more than 30% on news that the FDA had agreed to accept for review new analyses of data from the company's AMP-516 Phase III trial of its investigational treatment for chronic fatigue syndrome, Ampligen. The company's NASDAQ-quoted stock rose 6 cents to $0.34 on 11 July, valuing the company at $44.9 million.